According to the FDA, bisphosphonates increase the risks of femur fracture. The alarm raised by the Food and Drug Administration, in the US alone, interests some 5 million women who are taking drugs such as Fosamax, Boniva, Reclast and Actonel, marketed by Merck & Co, Roche, Novartis and Warner Chilcott respectively. The FDA warning could induce a switch to Prolia, a drug recently marketed by Amgen. . .